RU99100320A - Nasal administration of desmopressin - Google Patents

Nasal administration of desmopressin

Info

Publication number
RU99100320A
RU99100320A RU99100320/14A RU99100320A RU99100320A RU 99100320 A RU99100320 A RU 99100320A RU 99100320/14 A RU99100320/14 A RU 99100320/14A RU 99100320 A RU99100320 A RU 99100320A RU 99100320 A RU99100320 A RU 99100320A
Authority
RU
Russia
Prior art keywords
desmopressin
solution
volume
compound
group
Prior art date
Application number
RU99100320/14A
Other languages
Russian (ru)
Other versions
RU2173559C2 (en
Inventor
Бенгт Бенгтссон
Original Assignee
Ферринг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/667,047 external-priority patent/US5763398A/en
Application filed by Ферринг Б.В. filed Critical Ферринг Б.В.
Publication of RU99100320A publication Critical patent/RU99100320A/en
Application granted granted Critical
Publication of RU2173559C2 publication Critical patent/RU2173559C2/en

Links

Claims (15)

1. Фармацевтическая композиция в виде разовой дозы для назального введения, включающая в себя: водный раствор, имеющий объем от примерно 5 до примерно 75 мкл; и причем указанный раствор содержит от примерно 0,1 до примерно 2,0 мг/мл соединения, выбранного из группы, состоящей из десмопрессина, десмопрессина ацетата и фармацевтически приемлемой соли десмопрессина.1. A pharmaceutical composition in the form of a single dose for nasal administration, including: an aqueous solution having a volume of from about 5 to about 75 μl; and wherein said solution contains from about 0.1 to about 2.0 mg / ml of a compound selected from the group consisting of desmopressin, desmopressin acetate and a pharmaceutically acceptable salt of desmopressin. 2. Композиция по п.1, отличающаяся тем, что указанный раствор имеет объем от примерно 10 до примерно 50 мкл. 2. The composition according to claim 1, characterized in that said solution has a volume of from about 10 to about 50 μl. 3. Композиция по п.1, отличающаяся тем, что указанный раствор имеет объем от примерно 20 до примерно 45 мкл. 3. The composition according to claim 1, characterized in that said solution has a volume of from about 20 to about 45 μl. 4. Композиция по п.1, отличающаяся тем, что указанный раствор имеет объем примерно 35 мкл. 4. The composition according to claim 1, characterized in that said solution has a volume of about 35 μl. 5. Композиция по п.1, отличающаяся тем, что в указанном растворе имеется от примерно 0,1 до примерно 0,5 мг/мл указанного соединения. 5. The composition according to claim 1, characterized in that in said solution there is from about 0.1 to about 0.5 mg / ml of said compound. 6. Композиция по п.1, отличающаяся тем, что в указанном растворе имеется от примерно 0,5 до примерно 2,0 мг/мл указанного соединения. 6. The composition according to claim 1, characterized in that in said solution there is from about 0.5 to about 2.0 mg / ml of said compound. 7. Средство для доставки вместе с назальным распылительным насосом или устройством для капельного назального введения для многократного дозирования объема от примерно 5 до примерно 75 мкл водного раствора, содержащего от примерно 0,1 до примерно 2,0 мг/мл десмопрессина, десмопрессина ацетата или фармацевтически приемлемой соли десмопрессина. 7. A delivery device with a nasal spray pump or nasal drip device for repeatedly dispensing a volume of about 5 to about 75 μl of an aqueous solution containing about 0.1 to about 2.0 mg / ml desmopressin, desmopressin acetate, or pharmaceutically acceptable salt of desmopressin. 8. Средство по п.7, отличающееся тем, что указанный раствор имеет объем от примерно 10 до примерно 50 мкл. 8. The tool according to claim 7, characterized in that said solution has a volume of from about 10 to about 50 μl. 9. Средство по п.7, отличающееся тем, что указанный раствор имеет объем от примерно 20 до примерно 45 мкл. 9. The tool according to claim 7, characterized in that said solution has a volume of from about 20 to about 45 μl. 10. Средство по п.7, отличающееся тем, что указанный раствор имеет объем примерно 35 мкл. 10. The tool according to claim 7, characterized in that said solution has a volume of about 35 μl. 11. Способ подачи стойких плазменных уровней пептидного соединения, при котором назально вводят указанное соединение, выбранное из группы, состоящей из десмопрессина, десмопрессина ацетата и фармацевтически приемлемой соли десмопрессина, в от примерно 10 до примерно 75 мкл водного раствора, содержащего указанное соединение в диапазоне от примерно 0,1 до примерно 2,0 мг/мл указанного раствора. 11. A method for delivering stable plasma levels of a peptide compound, wherein said compound is nasally administered, selected from the group consisting of desmopressin, desmopressin acetate and a pharmaceutically acceptable salt of desmopressin, in about 10 to about 75 μl of an aqueous solution containing the compound in the range from about 0.1 to about 2.0 mg / ml of the specified solution. 12. Способ по п.11, отличающийся тем, что указанный объем находится в диапазоне от примерно 10 до примерно 50 мкл. 12. The method according to claim 11, characterized in that said volume is in the range from about 10 to about 50 μl. 13. Способ по п.11, отличающийся тем, что указанный объем находится в диапазоне от примерно 20 до примерно 45 мкл. 13. The method according to claim 11, characterized in that said volume is in the range from about 20 to about 45 μl. 14. Способ по п.11 для лечения мочевых расстройств, выбранных из группы, состоящей из несахарного диабета, недержания мочи, общего энуреза и ночного энуреза. 14. The method according to claim 11 for the treatment of urinary disorders selected from the group consisting of diabetes insipidus, urinary incontinence, general enuresis and nocturnal enuresis. 15. Изготовление лекарственного средства для лечения мочевых расстройств, выбранных из группы, состоящей из несахарного диабета, недержания мочи, общего энуреза и ночного энуреза, причем это лекарственное средство включает в себя соединение, выбранное из группы, состоящей из десмопрессина, десмопрессина ацетата и фармацевтически приемлемой соли десмопрессина, это лекарственное средство включает в себя от примерно 10 до примерно 75 мкл водного раствора, содержащего указанное соединение в диапазоне от примерно 0,1 до примерно 2,0 мг/мл указанного раствора. 15. The manufacture of a medicament for the treatment of urinary disorders selected from the group consisting of diabetes insipidus, urinary incontinence, general enuresis and nocturnal enuresis, the medicament comprising a compound selected from the group consisting of desmopressin, desmopressin acetate and a pharmaceutically acceptable desmopressin salts, this medication includes from about 10 to about 75 μl of an aqueous solution containing said compound in the range of from about 0.1 to about 2.0 mg / ml of said wow solution.
RU99100320/14A 1996-06-20 1997-06-10 Administration of desmopressin by nasal route RU2173559C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/667,047 1996-06-20
US08/667,047 US5763398A (en) 1996-06-20 1996-06-20 Nasal administration of desmopressin

Publications (2)

Publication Number Publication Date
RU99100320A true RU99100320A (en) 2000-11-27
RU2173559C2 RU2173559C2 (en) 2001-09-20

Family

ID=24676595

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99100320/14A RU2173559C2 (en) 1996-06-20 1997-06-10 Administration of desmopressin by nasal route

Country Status (24)

Country Link
US (1) US5763398A (en)
EP (1) EP0921786A1 (en)
JP (1) JP2000502358A (en)
KR (1) KR20000016781A (en)
CN (1) CN1233952A (en)
AU (1) AU707527B2 (en)
BR (1) BR9700797A (en)
CA (1) CA2258552A1 (en)
CZ (1) CZ420198A3 (en)
EE (1) EE9800453A (en)
HU (1) HUP9903541A3 (en)
IL (1) IL127572A (en)
LT (1) LT4621B (en)
LV (1) LV12230B (en)
NO (1) NO985936L (en)
NZ (1) NZ333124A (en)
PL (1) PL330902A1 (en)
RO (1) RO120170B1 (en)
RU (1) RU2173559C2 (en)
SI (1) SI9720040A (en)
SK (1) SK176998A3 (en)
TR (1) TR199802596T2 (en)
UA (1) UA49888C2 (en)
WO (1) WO1997048379A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
EP1121935B1 (en) * 2000-02-04 2008-08-13 Patents Exploitation Company B.V. Pharmaceutical composition containing a small or medium size peptide
JP2001233787A (en) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv Small-and medium-sized peptide-containing pharmacological composition
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
DK1530967T3 (en) * 2003-11-13 2006-07-03 Ferring Bv Blister pack and associated solid dosage form
SE528446C2 (en) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Pharmaceutical composition comprising desmopressin, silica and starch
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
ES2319054B1 (en) * 2007-08-06 2010-02-12 Gp Pharm S.A. ORAL PHARMACEUTICAL COMPOSITION OF DESMOPRESINA.
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
LT3225249T (en) * 2008-05-21 2019-01-10 Ferring B.V. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Solute concentration measurement device and related methods
US20120015880A1 (en) * 2008-12-22 2012-01-19 Seymour Fein Intranasal desmopressin administration
ES2929471T3 (en) 2009-06-18 2022-11-29 Acerus Pharmaceuticals Usa Llc Safe administration of desmopressin
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
FR2954774B1 (en) * 2009-10-30 2012-01-06 Michelin Soc Tech METHOD OF PREPARING A MASTER MIXTURE OF NATURAL RUBBER AND SILICA
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2605311C1 (en) * 2015-07-14 2016-12-20 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Method of treating pain syndrome in patients with degenerative-dystrophic disc diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (en) * 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Antidiuretic polypeptide
US4271068A (en) * 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
CH517705A (en) * 1969-12-16 1972-01-15 Ciba Geigy Ag Process for the production of cystine-containing peptides
US3929758A (en) * 1974-09-12 1975-12-30 Armour Pharma Cyclization of cysteine-containing peptides
US4033940A (en) * 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4093610A (en) * 1977-01-31 1978-06-06 American Home Products Corporation Process for producing triglycyl-lysine vasopressin and intermediates therefor
US4216141A (en) * 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
DE2923787A1 (en) * 1979-06-12 1980-12-18 Max Planck Gesellschaft METHOD FOR SELECTIVELY FORMING DISULFID BRIDGES IN POLYPEPTIDES AND THE PRODUCTS OBTAINED THEREOF AS MEDICINAL PRODUCTS
IE56021B1 (en) * 1982-10-13 1991-03-27 Akzo Nv Peptides
US5066716A (en) * 1988-12-13 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of chloroacetyl and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
US5500413A (en) * 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CZ282456B6 (en) * 1993-06-29 1997-07-16 Ferring B. V. Composition for nasal administration of desmopressin

Similar Documents

Publication Publication Date Title
RU99100320A (en) Nasal administration of desmopressin
RU2173559C2 (en) Administration of desmopressin by nasal route
US4778810A (en) Nasal delivery of caffeine
JP5599961B2 (en) Pharmaceutical composition
US5498598A (en) Composition for nasal administration of desmopressin
GB2349818A (en) Spray dispenser for opioid antagonists
CA2388610A1 (en) Oral transmucosal drug dosage using solid solution
EP1492519A1 (en) Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2009040595A1 (en) Multi-dose pharmaceutical composition of analgesic for nasal administration
JPH09502424A (en) Stabilized pharmaceutical peptide composition
CA2039456A1 (en) Osmotic dosage system for liquid drug delivery
AU2023202420A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
KR20110074767A (en) A device for administering liquid analgesics
US4973596A (en) Method of administering a narcotic analgesic and dosage forms therefor
MX2011006765A (en) Intranasal desmopressin administration.
JP2001089359A (en) Gel or gel preparation for nasal drip of analgesic component
US5055449A (en) Vincristine-containing product
KR0156929B1 (en) Stabilized water-soluble solution of pentamidine and its salts
MXPA97000440A (en) Pharmaceutical composition nasod administrable monodosis and method of application of such composic
CN1764424A (en) Unit dose delivery system for dental sensitivity product
CA2368184A1 (en) Method and means for treating post-polio syndrome
Raal et al. Farmaatsiaterminoloogia ja Euroopa farmakopöa
RU98104512A (en) METHOD AND COMPOSITION FOR TREATMENT OF ASTHMA
MX9700440A (en) Nasal administration of desmopressin.
RU2000109573A (en) METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY DEFICIENCY WITH THE USE OF OPTICALLY PURE (S) -SALMETEROL